First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE

被引：0
|
作者：
Wehrmann, C. [1 ]
Senftleben, S. [1 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S179 / S179
页数：1
相关论文
共 50 条
  • [1] First comparative dosimetric results after peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTA-NOC and Lu-177 DOTA-TATE
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S373 - S373
  • [2] Dosimetry in peptide receptor radionuclide therapy (PRRNT): comparative results using Lu-177 DOTA-TATE, DOTA-NOC und DOTA-TOC
    Schuchardt, C.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S244 - S244
  • [3] Lu-177 DOTA-TATE for peptide receptor Radionuclide therapy (PRRT): Organ, tumor, and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S358 - S359
  • [4] Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Wehrmann, Christiane
    Senftleben, Stefan
    Zachert, Carolin
    Mueller, Dirk
    Baum, Richard P.
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (03) : 406 - 416
  • [5] Dosimetry in peptide receptor Radionuclide therapy (PRRT) using Lu-177 DOTA-TATE: Intra- and interpatient variability
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S178 - S179
  • [6] Lu-177 DOTA-TATE for peptide receptor radionuclide therapy (PRRT): organ-, tumor- and blood kinetics
    Wehrmann, C.
    Senftleben, S.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S338 - S339
  • [7] Comparison of tumour and whole body absorbed doses of 177-Lu- DOTA-TATE and Lu-177 DOTA-NOC treatment in the same patient group
    Yeyin, N.
    Kabasakal, L.
    Akyel, R.
    Ocak, M.
    Toklu, T.
    Selcuk, N.
    Demir, M.
    Kanmaz, B.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S200 - S200
  • [8] Preliminary Results of Lu-177 DOTA-TATE Therapy in Patients with Neuroendocrine Tumor
    Hekimsoy, T.
    Isgoren, S.
    Gorur, G. Daglioz
    Demir, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S596 - S596
  • [9] Dosimetry using Lu-177 DOTATATE, Lu-177 HA-DOTATATE and Lu-177 DOTATOC: Comparative Results in Patients Undergoing Peptide Receptor Radionuclide Therapy (PRRT)
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Shafaei, S.
    Kropf, S.
    Wester, H. J.
    Baum, R. P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S224 - S225
  • [10] Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET)
    Mc Ewan, A.
    Wieler, M.
    Makis, W.
    McMullen, T.
    Morrish, D.
    MacLeod, S.
    Schrader, L.
    Sawyer, M.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 : 94 - 94
12345